From: Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Characteristic | Total | Advanced | Non-advanced | P-value |
---|---|---|---|---|
Number of patients | 105 | 50 | 55 | |
Administration without dose reduction | 35 (33.3) | 10 (20.0) | 25 (45.5) | 0.006 |
AEs leading to transient dose reduction | 5 (4.8) | 0 (0.0) | 5 (4.8) | 0.058 |
AEs leading to permanent dose reduction | 9 (8.6) | 6 (12.0) | 3 (5.5) | 0.304 |
AEs leading to permanent discontinuation | 56 (53.3) | 34 (68.0) | 22 (40.0) | 0.004 |